BioCryst Pharma (BCRX) Reports Q4 Loss Per Share of 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $7.78 +0.39%
EPS Growth %: -43.8%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
ORPB, PBCO, SICP, More
EPS Growth %: -43.8%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.06), $0.17 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $9 million versus the consensus estimate of $4.13 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- FVCBankcorp, Inc. (FVCB) Misses Q3 EPS by 2c
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
